Clinical trials / NCT05325710
Recruiting

Assessment of Personalized Follow-up in Prevention of Type 2 Diabetes

In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of…

I'm interested View official listing
ClinicalTrials.gov IDNCT05325710
PhaseNA
Enrollment230
SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche
Age18 Years – 75 Years
SexALL
I'm interested View official listing

Conditions studied

Diabete Type 2

About this study

In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of the disease would be present up to 20 years before the diagnosis. The Diagnosis is usually made around 40-50 years. The main factor of risk of T2D is the lifestyle, in particular a diet too rich for a too sedentary daily life. From a medico-economic point of view, chronic pathologies (including diabetes) account for 60% of insurance expenditure illness even though they concern 35% of insured persons, i.e. 20 million patients. The average annual repayment of a type 2 diabetic patient is 4890 euros. This study is part of this context as the starting point a reflection on a different, coordinated management, to know a preventive rather than a curative approach.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Patient, male or female, over the age of 18 * Patient with a FINDRISC score ≥10 points * Beneficiary of a French health insurance system * Patient having been informed and having given their consent free, enlightened and written Exclusion Criteria: * Patient over 75 years old * Patient already diagnosed with type 2 diabetes * Patient whose physical and/or psychological health is severely impaired, which according to the investigator may affect the compliance of the study participant. * Patient participating in another research * Patient in period of exclusion from another research always in progress at the time of inclusion. * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by court order or administration. * Pregnant, breastfeeding or parturient women. * Patient hospitalized without consent

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-05.